ArticleHealth science reports2026
The Effectiveness of Linezolid and Teicoplanin for Managing Infections After Burn Injuries: A Retrospective Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Gram-positive infections in burn patients present significant treatment challenges. This study compared the efficacy and safety of linezolid vs. teicoplanin for managing such infections in a clinical setting. Methods: We conducted a retrospective study involving 77 burn patients with confirmed Gram-positive infections at Shahid Motahari Hospital (2020-2022). Participants were allocated to: linezolid 600 mg BID ( Results: Linezolid demonstrated superior outcomes compared to teicoplanin: treatment duration was significantly shorter (5.68 ± 2.88 vs. 10.53 ± 6.86 days; mean difference -4.85 [95% CI -7.12 to -2.58], Conclusion: Linezolid showed significantly better efficacy than teicoplanin for Gram-positive burn infections, with reduced treatment duration and mortality while maintaining similar safety. Teicoplanin remains an alternative for specific cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.